Management Team

Roger J. Lias, Ph.D.
President, Director

Dr. Lias has been president of Avid Bioservices since September 2017. He most recently served as executive director, head of global biologics business development for Allergan plc., where he was responsible for developing and executing strategies designed to support the company’s business development activities related to innovative biologics, biosimilars and complex injectable products. In this role, he was instrumental in identifying, structuring and negotiating a biosimilars co-development collaboration with Amgen for four oncology biosimilar monoclonal antibody products. Prior to Allergan, Dr. Lias was president and group commercial director for Eden Biodesign, an established biopharmaceutical contract manufacturer and consultancy and wholly-owned subsidiary of Eden Biopharma Group. During his time with Eden Biodesign, he successfully transitioned the company’s CDMO client base from early-stage biotechnology companies to established biotechnology and multinational pharmaceutical companies, while also playing a key role in the eventual sale of Eden Biopharma Group to Watson Pharmaceuticals (now Allergan). Throughout his career, Dr. Lias has held senior management positions at several leading CDMOs including Cytovance Biologics, KBI BioPharma, Diosynth RTP (formerly Covance Biotechnology Services) and Lonza Biologics. At each of these companies, he was primarily charged with overseeing commercial operations, including growing and diversifying their respective client bases. During this time, Dr. Lias’ achievements ranged from building start-up Cytovance’s contract process development and biopharmaceutical cGMP production business, to significantly increasing revenues and transitioning the Diosynth organization from clinical to commercial supplier over a four-year period. Additionally, he has built a reputation as a highly regarded CDMO industry advocate who has contributed to the acceptance and growth of the biologics contract manufacturing market. Dr. Lias earned his Ph.D. from Clare College at the University of Cambridge in the United Kingdom.

 

Paul J. Lytle, CPA
Chief Financial Officer

Paul J. Lytle has served as Chief Financial Officer since August 2002 and has over 17 years of finance and accounting experience. Mr. Lytle oversees various functions, including finance and accounting, financial reporting, Corporate Governance, investor relations, human resources and information technology. Mr. Lytle started with Peregrine in March 1997 as Corporate Controller and has held positions of increasing responsibility at the Company. Mr. Lytle was promoted to Vice President of Finance and Accounting and was elected as the Company’s Corporate Secretary in 2000. Prior to joining Peregrine, Mr. Lytle worked for Deloitte & Touche LLP. Mr. Lytle holds a bachelor’s degree in business administration from the California State University, Long Beach and is a certified public accountant in the State of California and a member of the American Institute of Certified Public Accountants.

Tracy L. Kinjerski
Vice President, Business Operations

Tracy Kinjerski has more than 17 years of experience in the biopharmaceutical industry and joined Avid as the Vice President of Business Operations in November 2017. She most recently served as senior director of global business development at CMC Biologics, a global CDMO. In that role, her efforts spearheading business development and client relationship management generated significant new business growth in less than one year of joining the company. Prior to CMC Biologics, Ms. Kinjerski spent nearly five years with Fujifilm Diosynth Biotechnologies, the global CDMO division for Fujifilm. During her tenure, she served as director of commercial development focused on the East Coast of the US, helping to grow the company’s clinical and commercial business through new client engagements spanning global pharmaceutical companies, biotechnology companies of all sizes and government projects. Ms. Kinjerski, who holds a master’s degree in biomedical sciences, has also served in business and commercial development leadership positions at Althea Technologies and Avecia Biologics Billingham (since acquired by Fujifilm Diosynth), two fully-integrated CDMOs serving the pharmaceutical and biotechnology industries.

Connie Chang
Vice President, Quality

Connie Chang was appointed Vice President of Quality in October 2015. Ms. Chang joined the company in 2002 and has held a number of positions during her tenure. She was instrumental in leading the Process Sciences group that developed a number of processes which were successfully transferred into cGMP manufacturing and assays to characterize monoclonal antibodies and other proteins. In addition, she led the CMC team efforts for multiple internal Peregrine projects, including the preparation of the CMC section for IND and other regulatory filings. In her new role, Ms. Chang is responsible for leading both Peregrine’s and its wholly-owned subsidiary Avid Bioservices’ Quality groups to ensure that the companies’ multiple manufacturing facilities operate in full compliance with US and Global quality requirements. Prior to joining Avid, Ms. Chang worked for a company where she was responsible for the development and validation of saliva based assays for drugs which resulted in the issuance of two patents. Ms. Chang received her Bachelor of Science degree in Biochemistry from the California State University at Fullerton.

Gene Yoshioka
Senior Director, Manufacturing

Gene Yoshioka heads operations at Avid Bioservices and oversees its cGMP manufacturing. Gene originally joined the organization in 1995 (under Techniclone Corporation) and has almost 20 years in the industry, with experience at Amgen in Thousand Oaks, Biogen Idec in San Diego, and Peregrine Pharmaceuticals in Tustin. Gene brings broad experience, including quality control, manufacturing, supply management, and process development; working with an extensive list of different molecules. When Avid was founded in 2002, Gene managed the production team, helping to establish Avid as a successful commercially licensed contract manufacturing organization. Gene earned his bachelor’s degree in biology at the University of California, Irvine.

Ray Marzouk
Director, Quality Assurance (Commercial Products)

Ray Marzouk leads the quality assurance operations for commercial products at Avid Bioservices. He also heads the environmental monitoring program and microbiological testing functions. Ray has over 20 years in the biopharmaceutical and pharmaceutical industry serving in managerial, technical, and quality engineering capacities in a cGMP environment. Prior to joining Avid in 2007, Ray was with B. Braun Medical Inc. for twelve years in various quality control roles. Ray earned his bachelor’s degree in microbiology and molecular genetics from the University of California, Los Angeles. He obtained certification as a specialist microbiologist with the National Registry of Certified Microbiologists (NRCM).

Teresa Berry
Director, Engineering and Facilities

Teresa Berry heads the engineering and facilities departments at Avid Bioservices. With over 22 years of experience in the biopharmaceutical industry, she oversees the day-to-day facilities’ operations—from preventative maintenance and calibrations to construction projects. Teresa established robust cGMP programs for equipment and utility systems when she joined the organization in 2001, working for Avid’s parent company, Peregrine Pharmaceuticals, Inc. In 2002, Teresa played an integral role in launching and establishing Avid Bioservices as a successful contract manufacturing organization. Teresa holds a bachelor’s degree in health sciences from the University of California, Long Beach and is a member of the International Brotherhood of Electrical Workers, as a journeyman inside wireman. In addition, she is a long-standing member of the International Society for Pharmaceutical Engineering (ISPE). Teresa got her start in biotechnology with XOMA and Agensys, Inc. She also has more than 12 years’ experience in the construction industry, which enables her to serve Avid’s needs.

Board of Directors

Joseph Carleone, Ph.D.
Chairman

Dr. Carleone is Chairman of the Board of AMPAC Fine Chemicals LLC, a leading manufacturer of pharmaceutical active ingredients.  Prior to this position, Dr. Carleone was President, Chief Executive Officer and director of American Pacific Corporation, a leading custom manufacturer of fine and specialty chemicals and propulsion products.  Dr. Carleone has also served or currently serves as an officer and/or a director of several directly or indirectly wholly-owned subsidiaries of American Pacific Corporation.  Dr. Carleone received his bachelor’s degree in Mechanical Engineering from Drexel University, Philadelphia, Pennsylvania, in 1968; his master’s degree in Applied Mechanics from Drexel University in 1970; and his doctorate degree in Applied Mechanics from Drexel University in 1972.

Roger J. Lias, Ph.D.
President, Director

Dr. Lias has been president of Avid Bioservices since September 2017. He most recently served as executive director, head of global biologics business development for Allergan plc., where he was responsible for developing and executing strategies designed to support the company’s business development activities related to innovative biologics, biosimilars and complex injectable products. In this role, he was instrumental in identifying, structuring and negotiating a biosimilars co-development collaboration with Amgen for four oncology biosimilar monoclonal antibody products. Prior to Allergan, Dr. Lias was president and group commercial director for Eden Biodesign, an established biopharmaceutical contract manufacturer and consultancy and wholly-owned subsidiary of Eden Biopharma Group. During his time with Eden Biodesign, he successfully transitioned the company’s CDMO client base from early-stage biotechnology companies to established biotechnology and multinational pharmaceutical companies, while also playing a key role in the eventual sale of Eden Biopharma Group to Watson Pharmaceuticals (now Allergan). Throughout his career, Dr. Lias has held senior management positions at several leading CDMOs including Cytovance Biologics, KBI BioPharma, Diosynth RTP (formerly Covance Biotechnology Services) and Lonza Biologics. At each of these companies, he was primarily charged with overseeing commercial operations, including growing and diversifying their respective client bases. During this time, Dr. Lias’ achievements ranged from building start-up Cytovance’s contract process development and biopharmaceutical cGMP production business, to significantly increasing revenues and transitioning the Diosynth organization from clinical to commercial supplier over a four-year period. Additionally, he has built a reputation as a highly regarded CDMO industry advocate who has contributed to the acceptance and growth of the biologics contract manufacturing market. Dr. Lias earned his Ph.D. from Clare College at the University of Cambridge in the United Kingdom.

 

Mark R. Bamforth
Director

Mr. Bamforth has served as a member of the Board of Directors since October 2017. He currently serves as the president and CEO of Brammer Bio, a cell and gene therapy CDMO that he founded in 2015 and merged with Florida Biologix, an established, 10-year old CDMO, in March 2016.  In this role, he oversees a team of more than 300 employees providing services ranging from process development and early clinical supply services to production of Phase III clinical supplies and support for licensure of gene therapy products.  Previously, he founded Gallus BioPharmaceuticals, a biologics CDMO that experienced rapid growth leading to its acquisition by DPx Holdings B.V., the parent company of Patheon, in 2014 for $257.2 million.

Prior to his founding of Brammer Bio and Gallus BioPharmaceuticals, Mr. Bamforth spent 22 years with Genzyme Corporation rising to the position of senior vice president of corporate operations and pharmaceuticals.  In this role, he oversaw a multi-technology, global operations team comprised of more than 3,600 individuals at 13 internal sites and a network of 24 contract manufacturing organizations.  This team was charged with supplying over 20 commercial products and multiple clinical products that spanned biologics, cell therapy, gene therapy, pharmaceuticals and biologic devices.  While at Genzyme, Mr. Bamforth served as a member of the CEO’s operating committee, helping to guide corporate strategy acquisition, partnering and growth to over $4 billion in sales.

Mr. Bamforth also serves on the boards of MassBio and the Wentworth Institute of Technology, and is a Saltire Foundation founding-trustee. He earned a bachelor of science in chemical engineering from Strathclyde University and an MBA from Henley Management College.

 

 

.

 

Patrick Walsh
Director

Mr. Walsh has served as a member of the Board of Directors since October 2017. He currently serves as chief executive officer of Avista Pharma Solutions, a high-growth CDMO with over 220,000 square feet of facility space that provides pharmaceutical clients with a full suite of service offerings including analytical, microbiology, API, formulation, drug substance & drug product manufacturing expertise and capabilities.  Prior to joining Avista Pharma, he was chief executive officer of AAIPharma Services, a private-equity backed CDMO at which he led a successful growth strategy culminating in the company’s sale for more than 4.5 times return on invested capital.  Mr. Walsh also held the positions of president and chief operating officer of Gensia-Sicor, during which time he led the company’s commercial growth strategy, culminating in the eventual sale to Teva for $3.4 billion. Prior to Gensia, he spent 10 years in a global pharmaceutical company culminating in leading the U.S. and international business of a leading Japanese pharma company. Mr. Walsh has served on pharma boards as chairman, non-executive chairman and company director, as well as an executive advisor to private equity and venture capital firms.  He currently serves on the board of Avista Pharma, which is backed by private-equity firm Ampersand Capital Partners.

Gregory P. Sargen
Director

Gregory P. Sargen currently serves as Executive Vice President – Corporate Development and Strategy of Cambrex Corporation (NYSE:CBM) (“Cambrex”), a global manufacturer and provider of services to life sciences companies.  Prior to his current role, Mr. Sargen served as Executive Vice President and Chief Financial Officer of Cambrex.  Prior to Cambrex, Mr. Sargen served as Vice President of Finance – Chemicals Manufacturing Division of Fisher Scientific International Inc. (n/k/a Thermo Fisher Scientific Inc.) (NYSE:TMO), and held positions with Merck & Co., Inc. (NYSE:MRK), Heat and Control, Inc. and Deloitte & Touche LLP. Mr. Sargen is a Certified Public Accountant (non-practicing) and holds an MBA in Finance from The Wharton School of the University of Pennsylvania and a B.S. in Accounting from Pennsylvania State University.

Joel McComb
Director

Joel McComb is the CEO, Chairman and Co-Founder of BioSpyder Technologies, Inc. Prior to BioSpyder, Mr. McComb served as Senior Vice President and General Manager of Illumina, Inc., President of GE Healthcare’s Life Sciences and Discovery Systems division, and President of GE Healthcare’s Interventional Medicine division. Prior to GE Healthcare, Mr. McComb was the President, CEO and a director of Innovadyne Technologies, Inc., and held various positions at Beckman Coulter, Inc., and Charles River Laboratories (at the time a division of Bausch & Lomb Inc.) where he was a National Business Manager for the company’s monoclonal antibody CDMO division. Mr. McComb earned a Bachelor of Science degree in Genetics from the University of California, Davis and an MBA from Golden Gate University.

Richard B. Hancock
Director

Richard (Rick) B. Hancock has worked in the biologic CDMO industry for over 30 years in various operational and executive roles, serving most recently as President and CEO of Althea Technologies, Inc., a large molecule CDMO producing a wide range of biologics, vaccines and parenteral products. In addition to Althea, Mr. Hancock has held senior management positions at The Immune Response Corporation, and Hybritech Inc. (now part of Eli Lilly & Company), and he is currently the Chairman of the Board and Executive Director of Argonaut Manufacturing Services, Inc., a CDMO focused on the biotechnology and life sciences industries. Mr. Hancock received a BA in Microbiology from Miami University.